Bromides

LANNETT expands respiratory pipeline, signs exclusive distribution agreement for generic SPIRIVA® handihaler®

Retrieved on: 
Thursday, July 29, 2021
Chemical compounds, Health care, Health sciences, Muscarinic antagonists, Boehringer Ingelheim, Bromides, Epoxides, Thiophenes, Tiotropium bromide, Abbreviated New Drug Application, Inhaler

PHILADELPHIA, July 29, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an exclusive U.S. commercialization agreement for a therapeutically equivalent generic of Spiriva Handihaler (Tiotropium Bromide inhalation powder) with Respirent Pharmaceuticals Co. Ltd.

Key Points: 
  • PHILADELPHIA, July 29, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an exclusive U.S. commercialization agreement for a therapeutically equivalent generic of Spiriva Handihaler (Tiotropium Bromide inhalation powder) with Respirent Pharmaceuticals Co. Ltd.
  • U.S. sales of Spiriva Handihaler were $1.5 billion for the 12 months ending May, 2021 according to IQVIA, although actual generic market values are expected to be lower.
  • "With generic Spiriva Handihaler, our strategic relationship with Respirent now includes three inhaler products, each of which has the potential to be a meaningful contributor to our company's financial performance.
  • The generic Spiriva Handihaler product is currently in development and tracking to Abbreviated New Drug Application (ANDA) submission in 2023."

Hangzhou Chance Pharmaceuticals Announces NMPA Acceptance of Marketing Authorization Application for CXF11

Retrieved on: 
Friday, July 2, 2021
Respiratory diseases, Chemical compounds, Pulmonology, Chronic lower respiratory diseases, Muscarinic antagonists, Bromides, Epoxides, Thiophenes, Tiotropium bromide, Chronic obstructive pulmonary disease, COPD: Journal of Chronic Obstructive Pulmonary Disease, Bronchospasm

HANGZHOU, China, July 02, 2021 (GLOBE NEWSWIRE) -- Hangzhou Chance Pharmaceuticals (Chance), a clinical-stage biotechnology company focusing on discovering, developing, and commercializing transformative inhalation therapies for the worlds most debilitating diseases, announced that the National Medical Products Administration (NMPA) of China has accepted its Marketing Authorization Application for CXF11 for the treatment of chronic obstructive pulmonary disease (COPD).

Key Points: 
  • HANGZHOU, China, July 02, 2021 (GLOBE NEWSWIRE) -- Hangzhou Chance Pharmaceuticals (Chance), a clinical-stage biotechnology company focusing on discovering, developing, and commercializing transformative inhalation therapies for the worlds most debilitating diseases, announced that the National Medical Products Administration (NMPA) of China has accepted its Marketing Authorization Application for CXF11 for the treatment of chronic obstructive pulmonary disease (COPD).
  • The NMPA Acceptance of Marketing Authorization Application for CXF11is the first important milestone in product development for Chance.
  • CXF11 is Chances tiotropium bromide inhalation drug intended for prevention of bronchospasm in adults with chronic obstructive pulmonary disease (COPD).
  • Chance Pharmaceuticals is a clinical-stage biotechnology company focusing on discovering, developing and commercializing transformative inhalation therapies for the worlds most debilitating diseases.

2021 Global Barium Bromide (CAS 7791-28-8) Market Research Report - Downstream Industry Trends - ResearchAndMarkets.com

Retrieved on: 
Monday, May 31, 2021
Chemistry, Physical sciences, Natural sciences, Alkaline earth metals, Chemical elements, Barium compounds, Bromides, Metal halides, Barium bromide, Barium, Bromide, Radium

The "Barium bromide (CAS 7791-28-8) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Barium bromide (CAS 7791-28-8) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Barium bromide.
  • The Barium bromide global market report key points:
    The first chapter introduces the product (composition, structure, hazards, storage, toxicological & ecological information, etc.).
  • The fifth chapter deals with Barium bromide market trends and forecast, distinguish Barium bromide manufacturers and suppliers.

Global Hydrobromic Acid Market Insights (2020 to 2025) - Analysis and Forecast by Manufacturers, Regions, Technology, Application & Product Type - ResearchAndMarkets.com

Retrieved on: 
Friday, April 24, 2020
Chemicals, Plastics, Manufacturing, Chemical compounds, Bromides, Acids, Mineral acids, Hydrobromic acid

The "Hydrobromic Acid Market Insights 2020, Analysis and Forecast Global and Chinese Market to 2025, by Manufacturers, Regions, Technology, Application, Product Type" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hydrobromic Acid Market Insights 2020, Analysis and Forecast Global and Chinese Market to 2025, by Manufacturers, Regions, Technology, Application, Product Type" report has been added to ResearchAndMarkets.com's offering.
  • This report is a professional and in-depth study on the current state of the global Hydrobromic Acid market with a focus on the Chinese market.
  • Key points of Hydrobromic Acid Market Report:
    The report provides a basic overview of Hydrobromic Acid industry including: definition, applications and manufacturing technology.
  • Overall, the report provides an in-depth insight of 2015-2025 global and Chinese Hydrobromic Acid market covering all important parameters.

Brickell Biotech Announces Publication of its U.S. Phase 2b Study Results for Sofpironium Bromide in Patients with Primary Axillary Hyperhidrosis in the Journal of the American Academy of Dermatology

Retrieved on: 
Thursday, February 20, 2020
Physical sciences, Chemistry, Natural sciences, Hyperhidrosis, Thoracic surgery, Bromides, Metal halides, Bromide, Bromine, Iron(III) bromide

Sofpironium bromide is an innovative, retro-metabolically designed, anticholinergic new molecular entity under investigation for the topical treatment of primary axillary hyperhidrosis.

Key Points: 
  • Sofpironium bromide is an innovative, retro-metabolically designed, anticholinergic new molecular entity under investigation for the topical treatment of primary axillary hyperhidrosis.
  • We are encouraged by these Phase 2b study results and are pleased by the publication of these data in such a prestigious academic peer-reviewed journal, said Deepak Chadha, M.S.
  • These study results give us the confidence to continue to advance the development of sofpironium bromide.
  • The dermatology community needs new treatment options to effectively managehyperhidrosis patients and give them the quality of life they seek.

Verona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium Therapy

Retrieved on: 
Monday, January 13, 2020
Health, Dosage forms, Medicine, Asthma, Respiratory therapy, Bromides, Muscarinic antagonists, Metered-dose inhaler, Inhaler, Dry-powder inhaler, Nebulizer, Chronic obstructive pulmonary disease

The study met its primary endpoint of improved lung function, with ensifentrine added on to inhaled tiotropium, a LAMA commonly used to treat COPD.

Key Points: 
  • The study met its primary endpoint of improved lung function, with ensifentrine added on to inhaled tiotropium, a LAMA commonly used to treat COPD.
  • These data bring clarity to planning the design, including dose selection, endpoints and background therapy, of our Phase 3 program.
  • Full data from the Phase 2b study will be released at a subsequent scientific meeting, pending further data analysis.
  • Verona Pharma is currently in Phase 2 development with three formulations of ensifentrine for the treatment of COPD: nebulized, dry powder inhaler, and pressurized metered-dose inhaler.

Global Vanadium Market Review & Forecast 2013-2023: Data on Production, Consumption, Trade Statistics and Prices - ResearchAndMarkets.com

Retrieved on: 
Friday, October 25, 2019
Mining, Minerals, Natural Resources, Chemistry, Chemical elements, Physical sciences, Bromides, Metal halides, Vanadium compounds, Restorative dentistry, Vanadium

Comprehensive data showing vanadium worldwide production, consumption, trade statistics and prices are provided.

Key Points: 
  • Comprehensive data showing vanadium worldwide production, consumption, trade statistics and prices are provided.
  • Each country's market overview covers the following: vanadium production in the country, major manufacturers, vanadium consumption, vanadium trade.
  • The report offers a 5-year outlook on the reviewed market, including vanadium market volume predictions and prices trends.
  • Company's business and sales activities will be boosted by gaining an insight into the vanadium market.

Global Sodium Bromide Market 2019-2023: Market to Grow at a CAGR of 5.4%

Retrieved on: 
Wednesday, November 14, 2018
Chemistry, GABAA receptor positive allosteric modulators, Bromides, Chemical elements, Sedatives, Sodium compounds, Sodium bromide, Hypobromite, Bromine, Sodium, Compound annual growth rate

The "Global Sodium Bromide Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Sodium Bromide Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
  • The global sodium bromide market to grow at a CAGR of 5.40% during the period 2019-2023.
  • Global Sodium Bromide Market 2019-2023, has been prepared based on an in-depth market analysis with inputs from industry experts.
  • To calculate the market size, the report considers the revenue generated from the use of sodium bromide in different applications.